Published in Br J Cancer on August 12, 2002
Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol (2005) 1.14
Applications of nanotechnology in dermatology. J Invest Dermatol (2012) 1.00
MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation. Pigment Cell Melanoma Res (2014) 0.97
Novel, cysteine-modified chelation strategy for the incorporation of [M(I)(CO)(3)](+) (M = Re, (99m)Tc) in an α-MSH peptide. Bioconjug Chem (2012) 0.88
Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets. Curr Pharm Des (2015) 0.87
Clickable, hydrophilic ligand for fac-[M(I)(CO)3](+) (M = Re/(99m)Tc) applied in an S-functionalized α-MSH peptide. Bioconjug Chem (2014) 0.86
Melanocortin 1 receptor regulates melanoma cell migration by controlling syndecan-2 expression. J Biol Chem (2012) 0.85
Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery. Int J Nanomedicine (2012) 0.83
Malignant melanoma and melanocortin 1 receptor. Biochemistry (Mosc) (2013) 0.81
Subcellular trafficking and transfection efficacy of polyethylenimine-polyethylene glycol polyplex nanoparticles with a ligand to melanocortin receptor-1. J Control Release (2012) 0.81
Multivalent Interactions: Synthesis and Evaluation of Melanotropin Multimers - Tools for Melanoma Targeting. ACS Med Chem Lett (2012) 0.81
Trigonal scaffolds for multivalent targeting of melanocortin receptors. Org Biomol Chem (2015) 0.79
Novel modular transporters delivering anticancer drugs and foreign DNA to the nuclei of target cancer cells. J BUON (2009) 0.79
Promoters with cancer cell-specific activity for melanoma gene therapy. Acta Naturae (2011) 0.77
Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity. Br J Cancer (2015) 0.76
MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy. Sci Rep (2016) 0.76
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology (2010) 0.76
Preclinical Melanoma Imaging with (68)Ga-Labeled α-Melanocyte-Stimulating Hormone Derivatives Using PET. Theranostics (2017) 0.75
An electrochemical immunosensing method for detecting melanoma cells. Biosens Bioelectron (2015) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
The cloning of a family of genes that encode the melanocortin receptors. Science (1992) 4.64
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J (1986) 3.78
Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem (1993) 2.81
The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol (1992) 2.27
Molecular cloning of a novel melanocortin receptor. J Biol Chem (1993) 1.89
Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett (1992) 1.78
Regulation of tyrosinase in human melanocytes grown in culture. J Cell Biol (1983) 1.71
Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem Mol Biol Int (1996) 1.55
Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol (1998) 1.55
Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology (1996) 1.52
Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma (1981) 1.42
Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc Natl Acad Sci U S A (1995) 1.35
Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest (1994) 1.29
Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci U S A (1996) 1.25
Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res (1991) 1.22
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol (1997) 1.14
The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res (2000) 1.11
Anti-melanoma monoclonal antibody HMB45 identifies an oncofetal glycoconjugate associated with immature melanosomes. J Histochem Cytochem (1992) 1.08
Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res (2000) 1.07
alpha-MSH production, receptors, and influence on neopterin in a human monocyte/macrophage cell line. J Leukoc Biol (1996) 1.03
Molecular cloning of a novel human melanocortin receptor. Biochem Biophys Res Commun (1993) 1.01
Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes. J Immunol (1997) 1.00
Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. Br J Cancer (1997) 1.00
Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest (1990) 0.99
Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg (2001) 0.99
Detection of cytoplasmic S-100 protein in primary and metastatic intraocular melanomas. Invest Ophthalmol Vis Sci (1983) 0.96
Expression of the MC1 receptor gene in normal and malignant human melanocytes. A semiquantitative RT-PCR study. Cell Mol Biol (Noisy-le-grand) (1999) 0.94
Tyrosine levels regulate the melanogenic response to alpha-melanocyte-stimulating hormone in human melanocytes: implications for pigmentation and proliferation. Pigment Cell Res (2001) 0.92
Activation of cAMP-dependent protein kinase is required for optimal alpha-melanocyte-stimulating hormone-induced pigmentation. Exp Cell Res (1998) 0.91
Proopiomelanocortin and the immune-neuroendocrine connection. Ann N Y Acad Sci (1999) 0.89
The role of alpha-MSH as a modulator of cutaneous inflammation. Ann N Y Acad Sci (2000) 0.89
Human peripheral blood-derived dendritic cells express functional melanocortin receptor MC-1R. Ann N Y Acad Sci (1999) 0.88
Enhanced expression of melanocortin-1 receptor (MC1-R) in normal human keratinocytes during differentiation: evidence for increased expression of POMC peptides near suprabasal layer of epidermis. J Invest Dermatol (1999) 0.88
Nonrandom distribution of receptors for melanocyte-stimulating hormone on the surface of mouse melanoma cells. J Supramol Struct (1976) 0.86
Alpha-MSH causes a small rise in cAMP but has no effect on basal or ultraviolet-stimulated melanogenesis in human melanocytes. Br J Dermatol (1990) 0.86
Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res (1997) 0.86
Immunological localisation of melanocortin 1 receptor on the cell surface of WM266-4 human melanoma cells. Cancer Lett (1996) 0.85
Regulation of mammalian melanogenesis by tyrosinase inhibition. Differentiation (1989) 0.80
Immunohistochemical detection of the melanocortin 1 receptor in human testis, ovary and placenta using specific monoclonal antibody. Horm Res (1997) 0.80
Human keratinocytes express functional alpha-MSH (MC1-R) receptors. In Vitro Cell Dev Biol Anim (2001) 0.78
Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas. J Immunother (1997) 0.78
Thy-1+ dendritic cells express truncated form of POMC mRNA. Exp Dermatol (1995) 0.76
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Generic queries for meeting clinical information needs. Bull Med Libr Assoc (1993) 8.13
"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 7.61
Quantitative data on the inferior olivary nucleus in man, cat and vampire bat. J Comp Neurol (1968) 4.96
"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol (1975) 4.86
The MEDLINE Button. Proc Annu Symp Comput Appl Med Care (1992) 3.54
An analysis of the murine NK cell as to structure, function and biological relevance. Immunol Rev (1979) 3.15
The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood (2000) 3.09
Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol (1977) 3.05
Rapid fluorescence method for screening Salmonella spp. from enteric differential agars. J Clin Microbiol (1990) 2.84
Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells. Proc Natl Acad Sci U S A (1985) 2.65
[Socioeconomic determinants and utilization of emergency hospital services]. Med Clin (Barc) (1997) 2.57
What is the restriction point? Curr Opin Cell Biol (1995) 2.48
Exocytosis elicited by action potentials and voltage-clamp calcium currents in individual mouse pancreatic B-cells. J Physiol (1993) 2.47
Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo. Nature (1977) 2.39
A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst (1999) 2.36
Inositol trisphosphate-dependent periodic activation of a Ca(2+)-activated K+ conductance in glucose-stimulated pancreatic beta-cells. Nature (1991) 2.35
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol (2005) 2.32
Target-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J Immunol (1978) 2.29
From ICD9-CM to MeSH using the UMLS: a how-to guide. Proc Annu Symp Comput Appl Med Care (1993) 2.24
Cysticercosis and epilepsy: a critical review. Epilepsia (1998) 2.21
Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J Exp Med (1976) 2.11
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents (2002) 2.07
The recombinant 65-kD heat shock protein of Mycobacterium bovis Bacillus Calmette-Guerin/M. tuberculosis is a target molecule for CD4+ cytotoxic T lymphocytes that lyse human monocytes. J Exp Med (1988) 2.04
Value of microscopy in the diagnosis of dysentery associated with invasive Entamoeba histolytica. J Clin Pathol (1994) 2.03
Conserved regulation of proximodistal limb axis development by Meis1/Hth. Nature (1999) 2.03
Management of giant anal condyloma by wide local excision and anoplasty. Colorectal Dis (2012) 1.99
Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol (2001) 1.96
Natural killer cells in the mouse: an alternative immune surveillance mechanism? Contemp Top Immunobiol (1978) 1.96
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Role of the PI3K regulatory subunit in the control of actin organization and cell migration. J Cell Biol (2000) 1.94
NG2-positive cells in the mouse white and grey matter display distinct physiological properties. J Physiol (2004) 1.91
Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant (2011) 1.78
LAGE-1, a new gene with tumor specificity. Int J Cancer (1998) 1.76
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74
Analysis of electroencephalograms in Alzheimer's disease patients with multiscale entropy. Physiol Meas (2006) 1.73
Oral cysticercosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1995) 1.72
Cyclic ADP-ribose in beta cells. Science (1993) 1.71
Pesticide exposure and creatinine variation among young children. J Expo Anal Environ Epidemiol (2001) 1.71
Target--effector interaction in the natural killer cell system. I. Covariance and genetic control of cytolytic and target-cell-binding subpopulations in the mouse. Scand J Immunol (1978) 1.70
Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) (2009) 1.68
Radio imaging of the very-high-energy gamma-ray emission region in the central engine of a radio galaxy. Science (2009) 1.66
Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med (1994) 1.66
Very-high-energy gamma rays from a distant quasar: how transparent is the universe? Science (2008) 1.65
Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci (2001) 1.57
Prenatal and post-natal exposure to antibiotics and risk of asthma in childhood. Clin Exp Allergy (2015) 1.56
Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement. Osteoarthritis Cartilage (2005) 1.54
Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet (2001) 1.54
Neoadjuvant radiation and chemotherapy in rectal cancer does not increase postoperative complications. Int J Colorectal Dis (2003) 1.52
Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis. Clin Exp Immunol (1990) 1.51
Co-existence of peptide HI (PHI) and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man. Peptides (1984) 1.51
Human fetal thymus and bone marrow contain target cells for natural killer cells. Eur J Immunol (1981) 1.51
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol (1996) 1.51
YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol (1985) 1.51
Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med (1998) 1.50
The role of plasma amino acids in hepatic encephalopathy. Surgery (1975) 1.49
Tumor-induced immune dysfunction. Cancer Immunol Immunother (1999) 1.47
Generating MEDLINE search strategies using a librarian knowledge-based system. Proc Annu Symp Comput Appl Med Care (1993) 1.46
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
[Complications associated with percutaneous renal biopsy in Spain, 50 years later]. Nefrologia (2010) 1.43
Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin. Rev Esp Enferm Dig (2005) 1.43
Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature (1980) 1.42
Chronic thinner intoxication: clinico-pathologic report of a human case. J Neurol Neurosurg Psychiatry (1980) 1.40
Variable very-high-energy gamma-ray emission from the microquasar LS I +61 303. Science (2006) 1.40
Photoaggravated allergic contact dermatitis due to topical thiabendazole. Contact Dermatitis (1993) 1.40
Complications of central venous catheterization in critically ill children. Pediatr Crit Care Med (2001) 1.39
The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med (1989) 1.39
Angiographic outcome after intracoronary X-Sizer helical atherectomy and thrombectomy: first use in humans. Catheter Cardiovasc Interv (2002) 1.39
[The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia]. Med Clin (Barc) (1993) 1.38
[Thrombocytopenia associated with human immunodeficiency virus infection. Immunologic study of 60 patients addicted to parenteral drugs]. Med Clin (Barc) (1993) 1.38
High-speed rotational ablation (Rotablator) for unfavorable lesions in peripheral arteries. Cathet Cardiovasc Diagn (1993) 1.38
[Intraoperative intact parathyroid hormone determination as a predictive factor of hyperparathyroidism resolution]. Cir Esp (2006) 1.38
[Morbidity and costs in complete thyroidectomies. Improvement in Value of the Process by a change in the management]. Rev Calid Asist (2011) 1.38
Brain death and evoked potentials in pediatric patients. Crit Care Med (1999) 1.38
Natural killer cells. Prog Allergy (1981) 1.38
Reverse transcriptase polymerase chain reaction on fine needle aspirates for rapid detection of translocations in synovial sarcoma. Acta Cytol (1998) 1.38
Iron deficiency and iron overload in Swedish male adolescents. J Intern Med (1995) 1.37
The role of surgery and hyperalimentation in therapy of gastrointestinal-cutaneous fistulae. Ann Surg (1974) 1.37
Spatial and temporal expression of S100B in cells of oligodendrocyte lineage. Glia (2005) 1.34
Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol (1993) 1.33
The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J Immunol (1998) 1.33
Plasma amino acids in patients with hepatic encephalopathy. Effects of amino acid infusions. Am J Surg (1974) 1.32
Separate processes mediate nucleotide-induced inhibition and stimulation of the ATP-regulated K(+)-channels in mouse pancreatic beta-cells. Proc Biol Sci (1991) 1.32
Activation by adrenaline of a low-conductance G protein-dependent K+ channel in mouse pancreatic B cells. Nature (1991) 1.31
Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med (1999) 1.31
Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A (1992) 1.31
Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J Immunol (1982) 1.30
Non-responders to a postal questionnaire on respiratory symptoms and diseases. Eur J Epidemiol (1999) 1.30
Natural NK-cell targets in the mouse thymus: characteristics of the sensitive cell population. J Immunol (1979) 1.30
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 1.29
Syntaxin 1 interacts with the L(D) subtype of voltage-gated Ca(2+) channels in pancreatic beta cells. Proc Natl Acad Sci U S A (1999) 1.29
Antihypertensive effect and side-effects of bendroflumethiazide and propranolol. Acta Med Scand (1976) 1.29
Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension (2000) 1.29